The promise of GLP-1 receptor agonists for neurodegenerative diseases - PubMed
7 days ago
- #neuroprotection
- #neurodegenerative diseases
- #GLP-1 receptor agonists
- GLP-1 receptor agonists (GLP-1RAs) are emerging as potential treatments for neurodegenerative diseases.
- Preclinical studies show GLP-1RAs offer neuroprotective effects, including reduced protein aggregation and improved mitochondrial function.
- Epidemiological data suggests lower incidence of dementia, Parkinson's disease, and multiple sclerosis in long-term GLP-1RA users.
- Early human trials indicate signs of target engagement, such as slowed brain atrophy, but clinical outcomes are mixed.
- Challenges include uncertainty about optimal molecule choice, CNS penetrance, and patient adherence.
- Next-generation dual and triple agonists may offer greater efficacy but are untested in neurodegeneration.
- GLP-1RAs share benefits with exercise, such as enhancing insulin signaling and reducing inflammation.
- They are considered 'pharmacological analogues of exercise' and may have disease-modifying potential.
- Biomarker-driven, disease-specific trials are needed to confirm their long-term efficacy in neurodegenerative diseases.